These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 9179773)
21. Virus-neutralizing antibodies to hepatitis B virus: the nature of an immunogenic epitope on the S gene peptide. Waters J; Pignatelli M; Galpin S; Ishihara K; Thomas HC J Gen Virol; 1986 Nov; 67 ( Pt 11)():2467-73. PubMed ID: 2431101 [TBL] [Abstract][Full Text] [Related]
22. New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen. Kucinskaite-Kodze I; Pleckaityte M; Bremer CM; Seiz PL; Zilnyte M; Bulavaite A; Mickiene G; Zvirblis G; Sasnauskas K; Glebe D; Zvirbliene A Virus Res; 2016 Jan; 211():209-21. PubMed ID: 26541316 [TBL] [Abstract][Full Text] [Related]
24. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes. Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303 [TBL] [Abstract][Full Text] [Related]
25. Determination of the minimal length of preS1 epitope recognized by a monoclonal antibody which inhibits attachment of hepatitis B virus to hepatocytes. Sominskaya I; Pushko P; Dreilina D; Kozlovskaya T; Pumpen P Med Microbiol Immunol; 1992; 181(4):215-26. PubMed ID: 1279369 [TBL] [Abstract][Full Text] [Related]
26. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. Cornelius C; Schöneweis K; Georgi F; Weber M; Niederberger V; Zieglmayer P; Niespodziana K; Trauner M; Hofer H; Urban S; Valenta R EBioMedicine; 2016 Sep; 11():58-67. PubMed ID: 27568223 [TBL] [Abstract][Full Text] [Related]
27. Oral administration of a chimeric Hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice. Dobrica MO; Lazar C; Paruch L; van Eerde A; Clarke JL; Tucureanu C; Caras I; Ciulean S; Onu A; Tofan V; Branzan A; Urban S; Stavaru C; Branza-Nichita N Vaccine; 2018 Sep; 36(38):5789-5795. PubMed ID: 30082163 [TBL] [Abstract][Full Text] [Related]
28. Antibody responses to preS components after immunization of children with low doses of BioHepB. Madalinski K; Sylvan SP; Hellström U; Mikolajewicz J; Zembrzuska-Sadkowska E; Piontek E Vaccine; 2001 Oct; 20(1-2):92-7. PubMed ID: 11567751 [TBL] [Abstract][Full Text] [Related]
29. Assay of preS epitopes and preS1 antibody in hepatitis B virus carriers and immune persons. Deepen R; Heermann KH; Uy A; Thomssen R; Gerlich WH Med Microbiol Immunol; 1990; 179(1):49-60. PubMed ID: 1691815 [TBL] [Abstract][Full Text] [Related]
30. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. Usuda S; Okamoto H; Iwanari H; Baba K; Tsuda F; Miyakawa Y; Mayumi M J Virol Methods; 1999 Jun; 80(1):97-112. PubMed ID: 10403681 [TBL] [Abstract][Full Text] [Related]
31. Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library. Chen Y; Bai Y; Guo X; Wang W; Zheng Q; Wang F; Sun D; Li D; Ren G; Yin J Biologicals; 2016 Jul; 44(4):271-275. PubMed ID: 27255707 [TBL] [Abstract][Full Text] [Related]
32. Identification of neutralizing epitopes in the preS2 domain of the hepatitis B virus. Yato K; Matsuda M; Fukano K; Tanaka T; Moriishi K; Nishitsuji H; Shimotohno K; Tamura K; Wakita T; Muramatsu M; Kato T; Suzuki R Virus Res; 2023 Jan; 323():199014. PubMed ID: 36511290 [TBL] [Abstract][Full Text] [Related]
33. Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. Kohno H; Inoue T; Tsuda F; Okamoto H; Akahane Y J Gen Virol; 1996 Aug; 77 ( Pt 8)():1825-31. PubMed ID: 8760433 [TBL] [Abstract][Full Text] [Related]
34. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Sloan RD; Ijaz S; Moore PL; Harrison TJ; Teo CG; Tedder RS Antivir Ther; 2008; 13(3):439-47. PubMed ID: 18572757 [TBL] [Abstract][Full Text] [Related]
35. HepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-HBs and anti-preS1(21-47). Petit MA; Dubanchet S; Capel F; Voet P; Dauguet C; Hauser P Virology; 1991 Feb; 180(2):483-91. PubMed ID: 1703368 [TBL] [Abstract][Full Text] [Related]
36. Anti-PreS2 antibody assay for evaluating immune responses among recipients of recombinant hepatitis B PreS2 + S vaccine. Hurni WM; Roehm RR; Miller WJ J Med Virol; 1990 Feb; 30(2):146-50. PubMed ID: 2313274 [TBL] [Abstract][Full Text] [Related]
37. Immunological cross-reactivity between preS2 sequences of the hepatitis B virus envelope proteins corresponding to serological subtypes adw2 and ayw. Neurath AR; Kent SB; Adamowicz P; Riottot MM; Price P; Strick N; Parker K; Petit MA; Budkowska A; Girard M Mol Immunol; 1987 Jun; 24(6):561-8. PubMed ID: 3657796 [TBL] [Abstract][Full Text] [Related]
38. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Neurath AR; Seto B; Strick N Vaccine; 1989 Jun; 7(3):234-6. PubMed ID: 2476893 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals. Sankhyan A; Sharma C; Dutta D; Sharma T; Chosdol K; Wakita T; Watashi K; Awasthi A; Acharya SK; Khanna N; Tiwari A; Sinha S Sci Rep; 2016 Feb; 6():21240. PubMed ID: 26888694 [TBL] [Abstract][Full Text] [Related]
40. Humoral Immune Response in Mice Elicited by Combined Yeast-Derived Hepatitis B Virus Core, Surface, and Mosaic Surface Antigens. Granovski V; Yokosawa J; Rodrigues-Granovski V; Castro CC; Urbina AC; Granovski N Intervirology; 2017; 60(3):90-101. PubMed ID: 28957812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]